Patrick Langlois


Patrick Langlois has 30 years of international experience in health companies and health sector markets. His career began at the Louis Dreyfus Bank as an “Equity Research Analyst”. From January 1975 to December 1999 he held various posts in the Rhône-Poulenc Group, including Finance Director. From January 2000 to the end of 2004, Mr. Langlois worked at Aventis SA as Group Executive Vice President, Financial Director, and then in May 2002, Vice President Director. He has also been Senior Advisor to JP Morgan (2007-2008) and Rothschild (2005-2006).

Since 2005, Mr. Langlois he has been Associate Manager for PJL Conseils Eurl, a specialist strategic advisory company in Paris specializing in enterprise development and M&A activities for health sector companies.

Mr. Langlois holds a 3rd Cycle Diploma in Economics from the University of Rennes (1968) and a Higher Training Certificate in Banking (1974). He is also a board member for several pharmaceutical companies in France and overseas, including Stallergènes where he has been Chairman of the Executive Council since 2012. He is an Executive with the Scynexis Company and member of the Supervising Council for Innate Pharma and Newron Pharmaceuticals SpA.

Patrick Langlois

Khalil Barrage

Director  Representative of Invus

Khalil Barrage is a Managing Director at Invus, based in New York. He joined Invus in 2003 and established its Public Equity activity. Since its inception, Invus Public Equity has concentrated its investments in the emerging innovative biotech companies. Prior to joining Invus, he worked at The Olayan Group in New York and ran their US equity portfolio for 15 years. He holds a BA in Economics from the American University of Beirut. He is a member of the board of Protagenic and Celtaxsys. As part of his philanthropic engagement, Khalil serves on the board of the Children of Armenia Fund and Solving Kids’s Cancer. 


Julien Miara

Director  Representative of Invus
Julien Miara is a Director at Invus, he joined in 2010 as an analyst in the Public Equity group, covering Biotechnology among other sectors. In 2018, Julien was promoted to lead the team in Europe. Previously, Julien worked in investment banking at BNP Paribas in Paris and Société Générale in New-York, as well as in management consulting. Julien received his Master of Management from EDHEC Business School in Lille (France) in 2009. 
 Julien Miara

Cedric Moreau

Director  Representative of Sofinnova Partners

Cédric Moreau is a Partner in the Crossover investment team at Sofinnova Partners. He has 18 years of experience in life sciences investment banking and brings his transactional expertise in the biopharma industry. Previously, Cédric was Managing Director and Head of Healthcare Corporate Finance at ODDO-BHF, where the team was top ranked in 2017 in the European biotech equity capital market deals league tables. Prior to this, he was Director at Bryan Garnier & Co where he completed several sizeable cross border transactions, including NASDAQ listings for European companies. Before his corporate finance career, he spent 10 years as a Healthcare Equity Analyst and was several times EXTEL top ranked at Natixis and Fortis. He was in charge of both listed biotech and pharma companies coverage. Cédric holds a Master’s in Economics and post-graduate diploma in Finance and Taxation (Sorbonne) and diploma from the Société Française des Analystes Financiers (SFAF).

Sofinnova Cedric Moreau 2

Eric de la Fortelle

Independent Director

Dr. Forquenot de la Fortelle is a graduate of the Ecole Centrale de Paris, and holds the DEA (Higher Training Diploma) from Paris VI Pierre et Marie Curie, a doctorate from Paris XI Orsay and an MBA from INSEAD. He began his professional career as an academic researcher in life sciences involved in the discovery of many new medications, such as synchrotron LURE, Orsay and MRC-LMB, Cambridge) and later worked in biotech companies, including Structural GenomiX, Inc. in San Diego, CA and Hoffmann-La Roche in Basel. Subsequently, he was CEO of Delenex Therapeutics AG (Zurich) before returning to Seventure Partners on 1st January 2014 as a Venture Partner.

Eric Fortelle

Chahra Louafi

Permanent Representative of BPI investment

Mrs. Louafi is responsible for developing and implementing projects and creating companies within Mendel Partner, a private company incubator specializing in biotechnologies. She joined CDC Enterprises in 2001 as Investment Director, where she was responsible, amongst other things, for investment and biotechnology funds, particularly launch funds, and for technology transfer operations. In October 2009 Ms. Louafi joined the management team for InnoBio funds, a fund run by CDC Enterprises dedicated to biotechnology companies. She is also Chairman of the Inserm Initiative Transfer Monitoring Commission and a Member of Cap Décisif Management Committee.

Mrs. Louafi is a graduate of the Paris-Dauphine University (Masters Degree in Management Technology and Innovation), of the Paris X Nanterre University (Masters Degree in Company Finance), and of the National Agronomics Institute of Paris-Grignon (Masters Degree in Microbiology and Enzyme Engineering). She is also in on the Boards of DBV Technologies, Sensorion, Eyevensys, MedDay, Pixium Vision and Lysogène.

Chahra Louafi

Jean-François Morin


A graduate of EDHEC, Mr. Morin began his career in 2005 at MAZARS as a Financial Auditor.  In 2009 he joined CDC Enterprises, an InnoBio Funds Management company, as Financial Manager where he was involved in structuring several investment funds and value creation from participations, mostly in venture capital.  In September 2013, Mr. Morin joined the Laurent Arthaud team in InnoBio Funds as Head of Investment.

Jean Francois Morin

Nawal Ouzren

CEO of Sensorion

With fifteen years of experience in operational and strategic management within the pharmaceutical industry, Nawal Ouzren started out at Baxter, where she was Strategy and Operational Excellence Manager, Quality Operations Director and Senior Director Strategy before becoming Vice President of the BioSimilaires business unit. In 2014, she became Vice President of the Global Hemophilia Franchise at Baxalta, which had been incorporated within the Shire group. In 2016, she took control of the Shire group’s Global Genetic Diseases division, where she supervised all marketing, business and strategy aspects of this global division’s product portfolio.

NO borad of director







20190603 pipeline


Corporate presentation